Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014

Date: November 18, 2014
Pages: 58
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H7DD7947B27EN
Leaflet:

Download PDF Leaflet

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hyperphosphatemia In Chronic Kidney Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hyperphosphatemia In Chronic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hyperphosphatemia In Chronic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia In Chronic Kidney Disease Overview
Therapeutics Development
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance
Late Stage Products
Early Stage Products
Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
Amgen Inc.
OPKO Health, Inc.
Panion & Bf Biotech Inc
Sanofi
Vifor Pharma AG
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
bixalomer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fe-SAMMS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDX-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sucroferric oxyhydroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-505 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperphosphatemia In Chronic Kidney Disease - Recent Pipeline Updates
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
Aug 27, 2014: Velphoro receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis
Jun 27, 2014: Velphoro recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysis
Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting
Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex
Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency
Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan
Nov 28, 2013: Velphoro receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis
Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application
Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2014
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Amgen Inc., H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health, Inc., H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Sanofi, H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma AG, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Hyperphosphatemia In Chronic Kidney Disease Therapeutics - Recent Pipeline Updates, H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H2 2014
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2014
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

Amgen Inc.
OPKO Health, Inc.
Panion & Bf Biotech Inc
Sanofi
Vifor Pharma AG
Skip to top


Ask Your Question

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: